Skip to content


New Content Item

Featured review: EZH2 as a therapeutic target for multiple myeloma

This article by Dr. Tremblay-LeMay et al. reviews the evidence supporting the role of EZH2 in MM pathophysiology and drug resistance, with an emphasis on interactions between EZH2 and microRNAs, as well as the prognostic significance of EZH2 expression in MM. Furthermore, results from the pre-clinical studies of EZH2 inhibition in MM and currently available interim results from clinical trials of EZH2 inhibitors in haematological malignancies are presented.


Most accessed articles RSS

View all articles


Chung-Tsen Hsueh, Loma Linda University

Delong Liu, New York Medical College

Aims and scope

Biomarker Research is an open access, peer-reviewed journal that encompasses all aspects of biomarker investigation. Biomarker Research aims to publish original discoveries, novel concepts, commentaries and reviews related to biomarker investigation from all biomedical disciplines.

The study of biomarkers has evolved rapidly in the advance of personalized medicine and individual health. The identification and validation of biomarkers in drug discovery/development and in disease diagnosis, treatment, prognosis, and prevention play an essential role in the genome era. With a quick turnaround time from submission to publication and online feedback from readers, Biomarker Research strives to provide fast dissemination of novel findings and new knowledge.

Latest Tweets


Annual Journal Metrics

  • Speed
    40 days to first decision for reviewed manuscripts only
    32 days to first decision for all manuscripts
    99 days from submission to acceptance
    19 days from acceptance to publication

    56 Altmetric mentions